The role of glia in the physiology and pharmacology of glucagon‐like peptide‐1: implications for obesity, diabetes, neurodegeneration and glaucoma. (23rd November 2021)

• Record Type: Journal Article
• Authors: Cui, Qi N.; Stein, Lauren M.; Fortin, Samantha M.; Hayes, Matthew R.
• Is Part Of: British journal of pharmacology. Volume 179:Number 4(2022)
• Page Start: 715
• Page End: 726
• Publication Date: 2021-11-23
• Subjects: astrocyte -- beta cell -- blood glucose -- exendin -- food intake -- gliosis -- inflammation -- liraglutide -- macrophage -- microglia -- neuroprotection -- semaglutide; Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.15683
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : The medical applications of glucagon‐like peptide‐1 receptor (GLP‐1R) agonists is evergrowing in scope, highlighting the urgent need for a comprehensive understanding of the mechanisms through which GLP‐1R activation impacts physiology and behaviour. A new area of research aims to elucidate the role GLP‐1R signalling in glia, which play a role in regulating energy balance, glycemic control, neuroinflammation and oxidative stress. Once controversial, existing evidence now suggests that subsets of glia (e.g. microglia, tanycytes and astrocytes) and infiltrating macrophages express GLP‐1Rs. In this review, we discuss the implications of these findings, with particular focus on the effectiveness of both clinically available and novel GLP‐1R agonists for treating metabolic and neurodegenerative diseases, enhancing cognition and combating substance abuse. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc